课题基金 / 基金详情

项目摘要

项目成果

Effie W Petersdorf的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall goal of Project 1 is to define the genetic barriers to successful allogeneic hematopoietic cell transplantation (HCT). HCT from unrelated donors can cure blood disorders. Complete and precise donor HLA matching is associated with superior transplant outcome. However, risks of graft-versus-hostdisease and mortality are still increased compared to sibling donor transplantation. Furthermore, 20- 40% ofpatients who start a search fail to identify suitably matched donors. Criteria for selecting optimal mismatched donors are ill-defined. Recently, new information on,KIR receptors demonstrates the importance of HLA-KIR interactions in alloresponses after HCT. The long-term objectives of Project 1 are to improve theavailability, safety and efficacy of HCT by optimizing donor genetic selection. The specific aims are to: 1) define the extent to which availability of unrelated HCT can be increased through the use of HLA mismatcheddonors by identifying permissible mismatches; 2) identify new MHC-resident genes associated with transplant outcome, and 3) determine if HLA-KIR interactions modify risk of post-transplant complications. Successin achieving these goals will broaden the applicability of unrelated HCT to the treatment of blood disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunogenetics of Outcomes Disparities After Allogeneic HCT
  • 批准号:
    10659539
  • 项目类别:
  • 资助金额:
    $44.29万
  • 财政年份:
    2023
  • 负责人:
    Effie W Petersdorf
  • 依托单位:
Immunogenetics of Outcomes Disparities after Allogeneic HCT
Immunogenetics of Outcomes Disparities after Allogeneic HCT
  • 批准号:
    10441227
  • 项目类别:
  • 资助金额:
    $39.45万
  • 财政年份:
    2018
  • 负责人:
    Effie W Petersdorf
  • 依托单位:
Immunogenetics of Outcomes Disparities after Allogeneic HCT
  • 批准号:
    10601325
  • 项目类别:
  • 资助金额:
    $9.32万
  • 财政年份:
    2018
  • 负责人:
    Effie W Petersdorf
  • 依托单位:
海外基金